Key Financial Figures - Consolidated Results
Quarterly Performance (Q2 FY27 vs Q2 FY26)
- Revenue from Operations: ₹8,974.28 lakhs (vs ₹7,799.41 lakhs in Q2 FY26)
- Other Income: ₹413.71 lakhs (vs ₹323.64 lakhs in Q2 FY26)
- Total Income: ₹9,387.99 lakhs (vs ₹8,123.05 lakhs in Q2 FY26)
- Profit Before Tax: ₹821.53 lakhs (vs loss of ₹345.07 lakhs in Q2 FY26)
- Profit After Tax: ₹705.72 lakhs (vs loss of ₹361.56 lakhs in Q2 FY26)
- Basic EPS: ₹0.77 (vs loss of ₹0.39 in Q2 FY26)
Half-Yearly Performance (H1 FY27 vs H1 FY26)
- Revenue from Operations: ₹17,669.97 lakhs (vs ₹17,557.18 lakhs in H1 FY26)
- Profit Before Tax: ₹4,681.28 lakhs (vs loss of ₹1,751.52 lakhs in H1 FY26)
- Profit After Tax: ₹3,166.86 lakhs (vs loss of ₹1,783.53 lakhs in H1 FY26)
- Basic EPS: ₹3.44 (vs loss of ₹1.94 in H1 FY26)
Exceptional Items
- Profit on sale of shares in Gujarat Themis Biosyn Limited: ₹929.53 lakhs (recognized in Q1 FY27)
- Impact of Labour Codes: ₹86.53 lakhs (recognized in previous year)
Key Financial Figures - Standalone Results
Quarterly Performance (Q2 FY27 vs Q2 FY26)
- Profit After Tax: ₹389.08 lakhs (vs loss of ₹535.55 lakhs in Q2 FY26)
- Basic EPS: ₹0.42 (vs loss of ₹0.58 in Q2 FY26)
Half-Yearly Performance (H1 FY27 vs H1 FY26)
- Profit After Tax: ₹3,262.80 lakhs (vs loss of ₹2,072.92 lakhs in H1 FY26)
- Basic EPS: ₹3.54 (vs loss of ₹2.25 in H1 FY26)
Exceptional Items (Standalone)
- Profit on sale of shares: ₹996.68 lakhs
- Write-off of investment in subsidiary: ₹129.39 lakhs
- Impact of Labour Codes: ₹86.53 lakhs
Balance Sheet Highlights (Consolidated)
- Total Assets: ₹61,239.33 lakhs (vs ₹59,790.79 lakhs as of 31-Mar-2026)
- Cash and Cash Equivalents: ₹1,593.77 lakhs (vs ₹453.81 lakhs as of 31-Mar-2026)
- Total Borrowings: ₹7,763.00 lakhs (vs ₹10,009.12 lakhs as of 31-Mar-2026)
- Equity Share Capital: ₹921.00 lakhs (unchanged)
Cash Flow Statement (Consolidated)
- Net Cash from Operating Activities: negative ₹5,744.35 lakhs
- Net Cash from Investing Activities: positive ₹9,975.77 lakhs
- Net Cash from Financing Activities: negative ₹3,091.46 lakhs
- Net Increase in Cash: ₹1,139.96 lakhs
Subsidiaries and Associates Included
The financial results include:
- Subsidiaries: Themis Chemicals Private Limited, Artemis Biotech Limited, Dr. Themis Private Limited
- Associates: Gujarat Themis Biosyn Limited, Long Island Nutritionals Private Limited
- Joint Venture: Richter Themis Medicare (India) Private Limited
Auditor Review
The financial results were reviewed by M/s. Krishaan & Co., Chartered Accountants, who issued an unmodified review report.
Segment Information
The company operates in a single business segment - Pharmaceuticals.